Market Entry of Biosimilar Low-Molecular-Weight Heparins in Europe: Opportunities and Challenges

Abstract

This article examines the market entry of biosimilar low-molecular-weight heparins (LMWHs) in Europe by focusing on regulatory requirements, pricing, reimbursement, prescribing, and dispensing. The window for biosimilar LMWHs to enter the market is narrow on the supply side because of several factors. These include (1) regulatory requirements, including a quality dossier, clinical and nonclinical studies, pharmacodynamic and pharmacokinetic studies, immunogenicity studies, and a comparability exercise (but a reduction in clinical data requirements might be plausible in some cases); (2) prices of originator LMWHs are lower than those of other biologic products; (3) European prices of originator LMWHs are lower than those observed in the rest of the world; (4) research and development and manufacturing costs are substantial; (5) costs of active pharmaceutical ingredients have increased following the heparin contamination crisis; and (6) biosimilar LMWHs may be subjected to generic medicine pricing regulations. Furthermore, there are limited opportunities for biosimilar LMWHs on the demand side. This is because, although LMWHs have a large market volume in Europe, demand-side incentives for biosimilar LMWHs are largely absent, and the questions about interchangeability and substitution between originator and biosimilar LMWHs have yet to be fully resolved.

Keywords

market entry - low-molecular-weight heparin - biosimilar

• References

• 1 Gray E, Mulloy B. Biosimilar low molecular weight heparin products. J Thromb Haemost 2009; 7 (7) 1218-1221
• 2 Clark C. Heparin: generic or biosimilar?. Hospital Pharmacy Europe 2011; 56: 43-44
• 3 Chu R, Pugatch M. Biogenerics or biosimilars? Discussing the present, considering the future. Available at: http://www.stockholm-network.org/downloads/publications/Biosimilars_FINAL.pdf . Accessed October 5, 2011
• 4 European Commission. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union 2004; 34-57
• 5 McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011; 3 (2) 209-217
• 6 European Medicines Agency. Guideline on similar biological medicinal products. London, England: European Medicines Agency; 2006a. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf . Accessed October 28, 2011
• 7 European Medicines Agency. Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, England: European Medicines Agency; 2003. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003963.pdf . Accessed October 28, 2011
• 8 European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, England: European Medicines Agency; 2005a. Available at: http://www.triskel.com/2%20Guideline%20biotech%20derived%20proteins.pdf . Accessed October 26, 2011
• 9 European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, England: European Medicines Agency; 2005b. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf . Accessed October 24, 2011
• 10 European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London, England: European Medicines Agency; 2006b. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf . Accessed August 5, 2011
• 11 European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. London, England: European Medicines Agency; 2007. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003927.pdf . Accessed October 28, 2011
• 12 European Medicines Agency. Concept paper on the revision of the guideline on nonclinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins. London, England: European Medicines Agency; 2011a. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109588.pdf . Accessed October 28, 2011
• 13 European Medicines Agency. Reflection paper on the use of starting materials and intermediates collected from different sources in the manufacturing of biological medicinal products (Draft paper). London, England: European Medicines Agency; 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500123445.pdf . Accessed March 9, 2012
• 14 Auguste C, Dereux S, Martinez C, Anger P. New developments in quantitative polymerase chain reaction applied to control the quality of heparins. Anal Bioanal Chem 2011; 399 (2) 747-755
• 15 Huang Q, Xu T, Wang G-Y , et al. Species-specific identification of ruminant components contaminating industrial crude porcine heparin using real-time fluorescent qualitative and quantitative PCR. Anal Bioanal Chem 2012; 402 (4) 1625-1634
• 16 Harenberg J, Kakkar A, Bergqvist D , et al. Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost 2009; 7 (7) 1222-1225
• 17 European Medicines Agency. Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: non-clinical and clinical issues. London, England: European Medicines Agency; 2011b. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115611.pdf . Accessed October 28, 2011
• 18 European Medicines Agency. Guideline on clinical investigation of the pharmacokinetics of therapeutic proteins. London, England: European Medicines Agency; 2005c. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003031.pdf . Accessed October 28, 2011
• 19 Drouet L. Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?. Target Oncol 2012; 7 (Suppl. 01) S35-S42
• 20 Houiste C, Auguste C, Macrez C, Dereux S, Derouet A, Anger P. Quantitative PCR and disaccharide profiling to characterize the animal origin of low-molecular-weight heparins. Clin Appl Thromb Hemost 2009; 15 (1) 50-58
• 21 Walenga JM, Hoppensteadt D, Cunanan J , et al. Immunogenicity of low molecular weight heparins and their biosimilars. J Thromb Haemost 2009; 7 (Suppl. 02) 136
• 22 BioGeneriX. Follow-on Biologics Forum: the delivery of regulatory, legal and business strategies balanced by scientific debates. Presented at: Follow-on Biologics Forum; April 27–29, 2005; Washington, DC
• 23 Grabowski H, Cockburn I, Long G. The market for follow-on biologics: how will it evolve?. Health Aff (Millwood) 2006; 25 (5) 1291-1301
• 24 Holmes Jr DR, Becker JA, Granger CB, Limacher MC, Page II RL, Sila C. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation 2011; 124 (11) 1290-1310
• 25 Yoshida W. Studies on biosimilar medications. Jornal Vascular Brasileiro 2010; 9: 141-144
• 26 Kishimoto TK, Viswanathan K, Ganguly T , et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358 (23) 2457-2467
• 27 Kalodiki E, Fareed J. New and generic anticoagulants and biosimilars: safety considerations. Clin Appl Thromb Hemost 2011; 17 (2) 136-139
• 28 Research in China. Export Price Trend of Heparin Products in China, 2008-Jul. 2011 (USD/kg). Research in China; 2011. Available at: http://www.researchinchina.com/news/NewsContent.aspx?id=23343 . Accessed July 10, 2012
• 29 Health IMS. Health care data. London, England: IMS Health; 2011
• 30 Zuniga L, Calvo B. Biosimilars—the way forward. Hospital Pharmacy Europe 2010; 50: 33-34
• 31 Mellstedt H. The future of biosimilars. Hospital Pharmacy Europe 2010; 49: 33-34
• 32 Long M, Trout J, Akpinar P. Biosimilars: HGH to TNFS, how will payers respond?. Paper presented at: ISPOR 12th Annual European Congress; October 28, 2009; Paris, France
• 33 European Generic Medicines Association. Biosimilars handbook. Brussels, Belgium: European Generic Medicines Association; 2011: 1-54
• 34 Malhotra H. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biologicals 2011; 39 (5) 321-324
• 35 Jackson CM. Biosimilars: considerations with low molecular weight heparins. Clin Adv Hematol Oncol 2010; 8 (3) 163-167
• 36 Marcus P, Tapson VF. Background, scope of the problem, and therapeutic options. Chest Physician; September 2008. Available at: http://www.chestnet.org/downloads/about/chestPhysician/Sept08supplement.pdf . Accessed July 9, 2012
• 37 Liefner M. Biosimilars' price dynamic in Europe. London, England: Office of Health Economics; 2010
• 38 Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 2011; 3: 29-36
• 39 National Institute for Health and Clinical Excellence. Human growth hormone (somatropin) for the treatment of growth failure in children (review of NICE technology appraisal guidance 42). London, England: National Institute for Health and Clinical Excellence; 2010. Available at: http://guidance.nice.org.uk/TA188 . Accessed October 28, 2011
• 40 Scottish Medicines Consortium. Ratiograstim. Glasgow, Scotland: Scottish Medicines Consortium; 2009. Available at: http://www.scottishmedicines.org.uk/files/filgrastim__Ratiograstim__FINAL_Oct_2009_Revised_031109.doc_for_website.pdf . Accessed October 8, 2011
• 41 Scottish Medicines Consortium. Epoetin zeta. Glasgow, Scotland: Scottish Medicines Consortium; 2010. Available at: http://www.scottishmedicines.org.uk/smc/6094.html . Accessed October 8, 2011
• 42 Fareed J. Differentiation among the low-molecular-weight heparins. Chest Physician; September 2008. Available at: http://www.chestnet.org/downloads/about/chestPhysician/Sept08supplement.pdf . Accessed July 9, 2012
• 43 Fareed J, Leong WL, Hoppensteadt DA , et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004; 30 (6) 703-713
• 44 European Medicines Agency. Questions and Answers on biosimilar medicines. . London, England: European Medicines Agency; 2008. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf . Accessed October 4, 2011
• 45 Hodgson J. WHO guidelines presage US biosimilars legislation?. Nat Biotechnol 2009; 27 (11) 963-965
• 46 Moran N. Fractured European market undermines biosimilar launches. Nat Biotechnol 2008; 26 (1) 5-6
• 47 Federal Trade Commission. Emerging health care issues: follow-on biologic drug competition. Federal Trade Commission; 2009. Available at: http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf . Accessed October 6, 2011